I was born and raised in Pennsylvania and had an interest in cancer research from the time that I was a child. I was exposed to Fox Chase Cancer Center very early on and knew from that moment that I wanted to do something to help in the fight against cancer. I attended University of the Sciences in Philadelphia for both my undergraduate and graduate degree as the school had a strong emphasis on the sciences and health professions.
Read MoreWith over a decade of entrepreneurship and management experience, I’ve learned one enduring truth: obstacles become opportunities when met with hard work and dedication. Believing that anything is possible with perseverance and self-belief, I’ve discovered that the greatest gift is empowering others to believe in themselves as well.
Read MoreSuzanne Houssainy was unanimously chosen by the Board of ALK Positive, Inc. for the role among over 300 candidates, many of whom were truly exceptional. We feel that the long, solid experience and professionalism Suzanne brings to the table is going to help our organization get to the next level. Suzanne has over 25 years of experience in sales, management and leadership positions in both the for-profit and the nonprofit worlds
Read MoreBreak Through Cancer announces a new partnership with ALK Positive Inc. (ALK Positive), a foundation funded by patients with ALK-positive lung cancer and their families. ALK Positive and Break Through Cancer are joining forces to fund a new initiative in lung cancer research with the hope of creating durable responses and cures for patients with ALK-positive lung cancer.
ALK Positive is the first foundation partner to commit funding to Break Through Cancer for the initiative. Jointly, they hope to inspire other foundations, individual donors, and industry partners to join them as they work to build a coalition to support this life-saving effort.
Read MoreALK Positive Europe (APEU) was founded in 2022 and has its origin in a Facebook group of European patient advocates who were supported in the beginnings by Gina Hollenbeck.
In Europe, there are several patient organizations and groups that advocate for ALK-positive patients limited to their own countries.
The size of these associations and groups varies greatly from country to country - from 25 to over 550 members.
Read MoreALK Positive and the Lung Cancer Research Foundation (LCRF) are pleased to announce a groundbreaking research partnership to fund $2 million in ALK-positive lung cancer research over the next three years.
Read MoreIn only seven months as our Director of Research and Clinical Affairs, Dr. Ken Culver has made a tremendous impact with our organization. With over three decades of work in pediatrics, immunology, pharmaceutical drug development for cancer treatment, as well as laboratory research in 1990 that contributed to the first ever human gene therapy trial for the treatment of children with adenosine deaminase (ADA) deficiency. It's an inspiring interview with Ken - and we are fortunate to have him with us in a leadership position. Be Inspired!
Read MoreAs part of the ALK Positive mission statement the ALK Positive Inc Board of Directors is committed to assisting ALK patients worldwide. Whilst there are many international members in the independent ALK FB SG, we are also greatly encouraged by the numerous international patients and caregivers who have subscribed to our newsletter.
Read MoreTo transform advanced ALK-positive lung cancer into a chronic or curable disease, ALK Positive to award $1.75 million through their research award program
Patient organization ALK Positive, in partnership with LUNGevity Foundation, announced the 2022 recipients of the ALK Positive/LUNGevity ALK-Positive Lung Cancer Research Awards. The grant monies, totaling $1.75 million, were raised by ALK Positive and represent patients with ALK-positive non-small cell lung cancer themselves directly influencing the direction and focus of the research that affects their lives.
Read More(December 28, 2022) – ALK Positive Inc. (ALK Positive) and The Lung Cancer Research Foundation (LCRF) announce funding of two ALK-positive related lung cancer projects. These grants, totaling $500,000, are awarded to researchers whose projects are focused upon transforming care and improving outcomes for patients with ALK-positive non-small cell lung cancer (NSCLC).
Read MoreWe are excited to welcome Dr. Kenneth Culver as our first Director of Research & Clinical Affairs Dr. Culver worked for 20 years at Novartis Oncology where he contributed to the development of 12 compounds including ceritinib for ALK+ NSCLC. In his last role, he served as Head, US Thoracic Oncology Clinical Strategy and Lead for the Center of Excellence for Immuno-Oncology for US Clinical Development and Medical Affairs. Most recently, he was the Global Medical Affairs Leader for the Cell and Gene Oncology program at GlaxoSmithKline.
Read MoreThe ALK Positive annual summit was once again a huge success! This year the event was held both in Denver, Colorado and virtually (online). We had 250 individual registrations in-person and 850 virtual attendees. Check out or collection of photos from different days of the event. Look for news in the coming months about the 2023 ALK Summit - and we hope to see you there in person! #strongertogether
Read MoreNumerous tributes were written in the days and weeks following Gina’s passing in early June. This outpouring of love came as no surprise to those of us who were fortunate enough to know her. If you spent even a little time in the ALK Positive lung cancer world over the last five years, chances are very high that you knew of Gina. For the past three years she has served as the volunteer president of ALK Positive, Inc.,
Read More"Going to ASCO was a great opportunity to network and represent the organization, help move ALK to the top, and let people know who we are. I feel it was a productive conference, and we look forward to continuing better relationships with everyone. As a patient-led organization, it is important for us that they see us and know that we are representing all ALK patients and their families to help with more ALK research."
Read MoreHere are a few of the latest highlights of what our nonprofit has been up to since the last update: Our Research Review Panel has been working tirelessly to complete the process of selection of our 2022 Research Grant Awards. As of the time of this writing, successful applicants from the first round of applications are going through the second round in which full research proposals have been submitted and are currently being reviewed and assessed by the Research Review Panel and our independent scientific advisors
Read Moreoth the ALK Positive Board of Directors and the ALK Positive Committees are comprised of volunteer members from the ALK Positive Support Group, all ALK-positive patients, or caregivers themselves. The Board, Committees, and our new CEO, are all working together to improve the life expectancy and quality of life of ALK-positive cancer patients worldwide. Here are a few of the latest highlights of what our nonprofit has been up to since the last update:
Read More
